Abstract
Evidence regarding long-acting beta-agonist safety and specific step up and step down recommendations in children that have been published since the National Asthma Education Prevention Program Guidelines for the Diagnosis and Management Expert Panel Report 3 are reviewed. Despite several systematic reviews involving many thousands of patients, the safety of long-acting beta-agonists in children remains under debate. Although the role of inhaled corticosteroids has been well established in children, whether the ideal add on therapy should be a long-acting betaagonist or a leukotriene receptor antagonist, balancing efficacy with safety information, remains controversial. The ideal step down regimen to be used after asthma control has been achieved is similarly not well established. Additional research in children is needed to answer these questions, particularly in the youngest age groups.
Keywords: Asthma, guidelines, leukotriene receptor antagonists, long-acting beta-agonists, pediatric, pharmacotherapy
Current Pediatric Reviews
Title: Adjusting Controller Medications in Children: Evidence for Step Up and Down Choices after EPR-3
Volume: 8 Issue: 1
Author(s): Mona G. Tsoukleris, Donna Huynh and Jill A. Morgan
Affiliation:
Keywords: Asthma, guidelines, leukotriene receptor antagonists, long-acting beta-agonists, pediatric, pharmacotherapy
Abstract: Evidence regarding long-acting beta-agonist safety and specific step up and step down recommendations in children that have been published since the National Asthma Education Prevention Program Guidelines for the Diagnosis and Management Expert Panel Report 3 are reviewed. Despite several systematic reviews involving many thousands of patients, the safety of long-acting beta-agonists in children remains under debate. Although the role of inhaled corticosteroids has been well established in children, whether the ideal add on therapy should be a long-acting betaagonist or a leukotriene receptor antagonist, balancing efficacy with safety information, remains controversial. The ideal step down regimen to be used after asthma control has been achieved is similarly not well established. Additional research in children is needed to answer these questions, particularly in the youngest age groups.
Export Options
About this article
Cite this article as:
G. Tsoukleris Mona, Huynh Donna and A. Morgan Jill, Adjusting Controller Medications in Children: Evidence for Step Up and Down Choices after EPR-3, Current Pediatric Reviews 2012; 8 (1) . https://dx.doi.org/10.2174/157339612799746281
DOI https://dx.doi.org/10.2174/157339612799746281 |
Print ISSN 1573-3963 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6336 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Amidine-Based Bioactive Compounds for the Regulation of Arginine Metabolism
Mini-Reviews in Medicinal Chemistry Cigarette Smoke Exposure Inhibits Early Phase of Antibody Production through Inhibition of Immune Functions in Alveolar Macrophage
Current Respiratory Medicine Reviews Enteric Ecosystem Disruption in Autism Spectrum Disorder: Can the Microbiota and Macrobiota be Restored?
Current Pharmaceutical Design The Clinical Potential of Worms and their Products in Treating Inflammatory Diseases
Current Immunology Reviews (Discontinued) New Treatments for Allergy: Advances in Peptide Immunotherapy
Current Medicinal Chemistry CD147: A Novel Modulator of Inflammatory and Immune Disorders
Current Medicinal Chemistry Targeting Fibrosis in Systemic Sclerosis
Endocrine, Metabolic & Immune Disorders - Drug Targets Potential Association Between TLR4 and Chitinase 3-Like 1 (CHI3L1/YKL-40) Signaling on Colonic Epithelial Cells in Inflammatory Bowel Disease and Colitis-Associated Cancer
Current Molecular Medicine Clinical Signs, Prevention and Treatment of Viral Infections in Infants
Infectious Disorders - Drug Targets Phenolic Content in Traditionally Processed Erythrina indica L. Seeds: Antioxidant Potential and Type II Diabetes Related Functionality
Current Nutrition & Food Science Proinflammatory Cytokines and Sickness Behavior in Rheumatic Diseases
Current Pharmaceutical Design Differential Enhancement of T Helper Type 1 (Th1)/Th2 Cytokine Production by Natural Killer T Cells Through Negative Feedback Regulation with Cytokine-conditioned Dendritic Cells
Current Immunology Reviews (Discontinued) Evaluation of the <i>In Vivo</i> Acute Toxicity and <i>In Vitro</i> Hemolytic and Immunomodulatory Activities of the <i>Moringa oleifera</i> Flower Trypsin Inhibitor (MoFTI)
Protein & Peptide Letters In silico and In vivo Toxicological Evaluation of Cissampelos Sympodialis Secondary Metabolites in Rattus Norvegicus
Current Drug Metabolism Pharmacological Approaches in the Treatment of Atrial Fibrillation
Current Medicinal Chemistry Manoyl-Oxide Biotransformations with Filamentous Fungi
Current Organic Chemistry Start Small and Stay Small: Minimizing Attrition in the Clinic with a Focus on CNS Therapeutics
Current Topics in Medicinal Chemistry Effect of HPMC - E15 LV premium Polymer on Release Profile and Compression Characteristics of Chitosan/ Pectin Colon Targeted Mesalamine Matrix Tablets and in vitro Study on Effect of pH Impact on the Drug Release Profile
Recent Patents on Drug Delivery & Formulation Ginsenosides from the Leaves and Flower Buds of Panax ginseng and their Pharmacological Effects
Current Bioactive Compounds The Adenosine A2b Receptor: Its Role in Inflammation
Endocrine, Metabolic & Immune Disorders - Drug Targets